STOCK TITAN

Cuprina Reaffirms Commitment to Shareholders and Patients Following Recent Stock Market Activity

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Cuprina Holdings (NASDAQ:CUPR) has issued a statement addressing recent unusual trading volatility in its stock. The company emphasized that it remains fully operational and legally compliant, with no known operational reasons or material adverse events causing the stock fluctuations.

CEO David Quek confirmed that no initial shareholders or founding team members have sold their stock in the past week. The company is progressing with key milestones, including FDA clearance submission for medical maggot therapy, expansion into the GCC region, and exploring potential joint ventures in chronic wound management.

Cuprina, which completed its IPO earlier this year, maintains its commitment to transparency and execution of its business plan while focusing on advancing its biotherapeutic pipeline.

Cuprina Holdings (NASDAQ:CUPR) ha pubblicato una nota relativa alla recente volatilità anomala delle azioni. La società ha sottolineato di essere pienamente operativa e conforme alle normative, senza evidenza di cause operative o eventi negativi rilevanti che possano spiegare le oscillazioni del titolo.

Il CEO David Quek ha confermato che nei giorni scorsi né azionisti iniziali né membri del team fondatore hanno venduto le proprie azioni. L’azienda procede con le tappe previste, tra cui la presentazione per l’autorizzazione FDA della terapia con larve mediche, l’espansione nel Gulf Cooperation Council (GCC) e la valutazione di joint venture nel campo della gestione delle ferite croniche.

Cuprina, che ha completato l’IPO all’inizio di quest’anno, ribadisce l’impegno alla trasparenza e all’esecuzione del piano industriale, continuando a puntare sullo sviluppo della sua pipeline bioterapeutica.

Cuprina Holdings (NASDAQ:CUPR) emitió un comunicado sobre la reciente volatilidad inusual en la cotización de sus acciones. La compañía afirmó que se mantiene totalmente operativa y en cumplimiento legal, sin identificar razones operativas ni eventos adversos materiales que expliquen las fluctuaciones.

El CEO David Quek confirmó que ningún accionista inicial ni miembro del equipo fundador ha vendido acciones en la última semana. La empresa avanza en hitos clave, incluida la presentación para la aprobación de la FDA de la terapia con larvas médicas, la expansión en la región del GCC y la exploración de posibles joint ventures en el manejo de heridas crónicas.

Cuprina, que completó su oferta pública inicial a principios de este año, mantiene su compromiso con la transparencia y la ejecución de su plan de negocio, enfocándose en el avance de su cartera bioterapéutica.

Cuprina Holdings (NASDAQ:CUPR)는 최근 주가의 이례적 변동성에 대해 성명을 발표했습니다. 회사는 완전 가동 중이며 법규를 준수하고 있다고 강조했으며, 주가 변동을 설명할 운영상 이유나 중요한 불리한 사건은 확인되지 않았습니다.

CEO David Quek는 초기 주주나 창업 멤버가 지난 주에 주식을 매도하지 않았다고 확인했습니다. 회사는 의료용 구더기 치료에 대한 FDA 승인 신청을 포함한 주요 마일스톤을 진행 중이며, GCC 지역으로의 확장과 만성 상처 관리 분야에서의 합작 투자 가능성도 모색하고 있습니다.

올해 초 IPO를 완료한 Cuprina는 투명성과 사업계획 실행에 대한 의지를 유지하며 생물치료제 파이프라인의 진전에 주력하고 있습니다.

Cuprina Holdings (NASDAQ:CUPR) a publié une déclaration concernant la récente volatilité inhabituelle de son titre. La société a souligné qu’elle demeure entièrement opérationnelle et en conformité légale, sans raisons opérationnelles connues ni événements défavorables significatifs expliquant ces fluctuations.

Le PDG David Quek a confirmé que aucun actionnaire initial ni membre de l’équipe fondatrice n’a vendu d’actions au cours de la semaine passée. L’entreprise progresse sur des jalons clés, notamment la dépôt pour l’autorisation FDA de la thérapie par larves médicales, l’expansion dans la région du CCG et l’exploration de coentreprises potentielles pour la prise en charge des plaies chroniques.

Cuprina, qui a finalisé son IPO au début de cette année, réaffirme son engagement en faveur de la transparence et de l’exécution de son plan d’affaires, tout en se concentrant sur l’avancement de sa pipeline biothérapeutique.

Cuprina Holdings (NASDAQ:CUPR) hat eine Stellungnahme zur jüngsten ungewöhnlichen Handelsvolatilität seiner Aktie veröffentlicht. Das Unternehmen betonte, dass es voll einsatzfähig und rechtlich compliant sei und keine bekannten operativen Gründe oder wesentlichen negativen Ereignisse vorlägen, die die Kursschwankungen erklären könnten.

CEO David Quek bestätigte, dass weder frühe Aktionäre noch Gründungsmitglieder in der vergangenen Woche Aktien verkauft haben. Das Unternehmen macht Fortschritte bei wichtigen Meilensteinen, darunter die Einreichung zur FDA-Freigabe der medizinischen Maden-Therapie, die Expansion in die GCC-Region und die Prüfung möglicher Joint Ventures im Bereich der Behandlung chronischer Wunden.

Cuprina, das Anfang dieses Jahres seinen Börsengang abgeschlossen hat, bekräftigt sein Engagement für Transparenz und die Umsetzung des Geschäftsplans und konzentriert sich auf die Weiterentwicklung seiner biotherapeutischen Pipeline.

Positive
  • No stock sales by initial shareholders or founding team members, showing confidence in company
  • FDA clearance submission for medical maggot therapy in progress
  • Geographic expansion into GCC region underway
  • Actively exploring M&A opportunities in wound management
Negative
  • Unusual stock trading volatility raising investor concerns
  • Recent IPO company still establishing market presence

Insights

Cuprina's response to unusual trading volatility offers reassurance but lacks specific financial details to fully address investor concerns.

Cuprina's public statement addressing recent stock volatility represents a classic corporate response to market uncertainty. The company is taking a defensive posture by emphasizing three key points: operational stability, insider stock retention, and ongoing business execution. However, the statement is notably light on quantitative information.

The lack of specific financial metrics or performance indicators is significant. While management asserts the company is in a "healthy position," they provide no concrete financial data to substantiate this claim. This communication strategy focuses on qualitative reassurance rather than quantitative proof.

Most revealing is the company's explicit statement that it has no knowledge of material adverse events that could explain the stock volatility. This carries regulatory significance as public companies must disclose material information. The retention of shares by founding team members and initial shareholders suggests internal confidence, though without disclosure of exact ownership percentages or lockup details.

The pipeline updates regarding FDA clearance applications, GCC regional expansion, and M&A exploration reaffirm previously communicated strategic directions rather than announcing new developments. These represent continuity of existing plans rather than new catalysts.

This statement appears designed primarily to stabilize market perception during a period of unexplained volatility, functioning more as reputation management than material financial disclosure. For investors, the reassurance of operational continuity must be weighed against the absence of updated financial performance metrics.

Singapore, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”) issued the following statement in response to recent unusual trading activity and speculation surrounding the Company.

Over the past week, the Company’s stock has experienced heightened trading volatility, which we understand has raised concerns among some shareholders. We want to take this opportunity to reaffirm that Cuprina is a fully operational, legally compliant, and mission-driven biotechnology company. We remain focused on advancing our pipeline, expanding access to our biotherapeutic solutions, and delivering long-term value to patients, clinicians, and shareholders alike.

“We recognize that some investors have questions following Friday’s unusual trading activity. The Company is not aware of any operational reasons for this stock price volatility nor of any material adverse events which may have led to this activity. Let us be clear: Cuprina is operationally in a healthy position and is diligently executing on its business plan since the Company’s Initial Public Offering earlier this year. We are a Nasdaq-listed company with audited financials, an expanding footprint in Asia and beyond, and a pipeline of regulated medical products serving and benefitting real patients in need. Our team continues to work tirelessly to commercialize breakthrough biologics and scale our global partnerships. While share price volatility is largely outside of our control, execution and transparency remain firmly within it,” said David Quek, Chief Executive Officer and Executive Director of Cuprina.

The Company also emphasizes that, to its knowledge, none of the Company’s initial shareholders or founding team members have sold their stock over the past week. This underscores our collective confidence in the Company’s mission, strategy, and long-term growth potential.

The Company remains on track with its operational and regulatory milestones, including:
                •             Submission of FDA clearance for its medical maggot therapy;
                •             Expansion of maggot distribution to the Gulf Cooperation Council (GCC) region;
                •             Exploring potential joint ventures and mergers & acquisitions to build a continuum of care in chronic wound management products.

Cuprina will continue to keep shareholders updated on key developments and milestones through timely disclosures and filings. We deeply value the trust and support of our shareholders and are committed to communicating with transparency and integrity, and delivering on our business and market share growth as communicated to our valued shareholders.

About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https://www.cuprina.com.  

Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg

Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com


FAQ

What caused the recent stock volatility in Cuprina (NASDAQ:CUPR) shares?

According to the company statement, Cuprina is not aware of any operational reasons or material adverse events that caused the recent stock price volatility.

Have any Cuprina (CUPR) insiders sold shares during the recent volatility?

No, the company stated that none of the initial shareholders or founding team members have sold their stock over the past week.

What are Cuprina's (CUPR) main business milestones for 2025?

Key milestones include FDA clearance submission for medical maggot therapy, expansion into the GCC region, and exploring joint ventures in chronic wound management.

When did Cuprina (CUPR) complete its IPO?

Cuprina completed its Initial Public Offering (IPO) earlier in 2025.

What is Cuprina's (CUPR) main business focus?

Cuprina is a biotechnology company focused on developing biotherapeutic solutions and medical maggot therapy for chronic wound management.
Cuprina Holdings (Cayman) Limited

NASDAQ:CUPR

CUPR Rankings

CUPR Latest News

CUPR Latest SEC Filings

CUPR Stock Data

6.19M
3.75M
1.67%
1.42%
Medical Instruments & Supplies
Healthcare
Link
Singapore
Singapore